📊 VTRS Key Takeaways
Is Viatris Inc (VTRS) a Good Investment?
Viatris exhibits severe operational deterioration with negative operating income, inability to cover interest expenses from operations (interest coverage: -0.7x), and nearly flat revenue growth (0.3% YoY). The 454% collapse in net income year-over-year combined with negative operating margins indicates fundamental profitability issues in the pharmaceutical business that threaten long-term debt serviceability despite positive free cash flow.
Viatris shows weak core profitability, with deeply negative operating and net margins, a sharp deterioration in earnings, and negative interest coverage that signals meaningful pressure on the income statement. While the company still generates solid operating cash flow and free cash flow, the combination of flat revenue growth, large net losses, and meaningful debt limits the quality of the fundamental profile.
Viatris Inc Key Strengths (VTRS)
- Positive free cash flow of $348.4M provides operational liquidity buffer
- Current ratio of 1.60x indicates adequate short-term liquidity position
- Gross margin of 32.9% demonstrates remaining product pricing power
- Positive operating cash flow and $1.94B of free cash flow provide financial flexibility
- Gross margin of 35.1% indicates the business still retains underlying product-level profitability before overhead and non-operating pressures
- Balance sheet liquidity is adequate with a 1.38x current ratio and positive equity base of $14.71B
VTRS Stock Risks: Viatris Inc Investment Risks
- Negative operating income (-$79.7M) and negative interest coverage (-0.7x) indicates inability to service $12.4B debt from operations
- Net income collapsed 454% YoY with EPS down 466%, signaling severe operational deterioration and potential structural decline
- Revenue growth of only 0.3% YoY with ROE of 1.2% and ROA of 0.5% reflects weak competitive position and deteriorating asset utilization
- High debt leverage ($12.4B long-term debt) combined with negative operating performance creates solvency stress
- Operating margin of -18.6% and net margin of -24.6% show severe profitability weakness
- Net income declined sharply year over year, suggesting deteriorating earnings quality and possible structural business pressure
- Negative interest coverage and $12.48B in long-term debt increase financial risk if profits do not recover
Key Metrics to Watch
- Operating income return to positive territory and operating margin expansion
- Interest coverage ratio recovery above 2.0x to ensure debt serviceability
- Revenue growth acceleration above low single digits
- Free cash flow sustainability and operating cash flow trends
- Operating margin recovery and interest coverage improvement
- Revenue growth consistency alongside free cash flow sustainability
Viatris Inc (VTRS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Viatris Inc presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
VTRS Profit Margin, ROE & Profitability Analysis
VTRS vs Healthcare Sector: How Viatris Inc Compares
How Viatris Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Viatris Inc Stock Overvalued? VTRS Valuation Analysis 2026
Based on fundamental analysis, Viatris Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Viatris Inc Balance Sheet: VTRS Debt, Cash & Liquidity
VTRS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Viatris Inc's revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $0.05 reflects profitable operations.
VTRS Revenue Growth, EPS Growth & YoY Performance
VTRS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.2B | $176.4M | $0.15 |
| Q3 2025 | $3.7B | $94.8M | $0.08 |
| Q2 2025 | $3.6B | -$4.6M | $0.00 |
| Q1 2025 | $3.2B | $113.9M | $0.09 |
| Q3 2024 | $3.7B | $94.8M | $0.08 |
| Q2 2024 | $3.8B | -$212.5M | $-0.18 |
| Q1 2024 | $3.7B | $113.9M | $0.09 |
| Q3 2023 | $3.9B | $331.6M | $0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Viatris Inc Dividends, Buybacks & Capital Allocation
VTRS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Viatris Inc (CIK: 0001792044)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTRS
What is the AI rating for VTRS?
Viatris Inc (VTRS) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTRS's key strengths?
Claude: Positive free cash flow of $348.4M provides operational liquidity buffer. Current ratio of 1.60x indicates adequate short-term liquidity position. ChatGPT: Positive operating cash flow and $1.94B of free cash flow provide financial flexibility. Gross margin of 35.1% indicates the business still retains underlying product-level profitability before overhead and non-operating pressures.
What are the risks of investing in VTRS?
Claude: Negative operating income (-$79.7M) and negative interest coverage (-0.7x) indicates inability to service $12.4B debt from operations. Net income collapsed 454% YoY with EPS down 466%, signaling severe operational deterioration and potential structural decline. ChatGPT: Operating margin of -18.6% and net margin of -24.6% show severe profitability weakness. Net income declined sharply year over year, suggesting deteriorating earnings quality and possible structural business pressure.
What is VTRS's revenue and growth?
Viatris Inc reported revenue of $3.5B.
Does VTRS pay dividends?
Viatris Inc pays dividends, with $266.0M distributed to shareholders in the trailing twelve months.
Where can I find VTRS SEC filings?
Official SEC filings for Viatris Inc (CIK: 0001792044) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTRS's EPS?
Viatris Inc has a diluted EPS of $0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VTRS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Viatris Inc has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VTRS stock overvalued or undervalued?
Valuation metrics for VTRS: ROE of 1.2% (sector avg: 15%), net margin of 5.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VTRS's AI grade for 2026?
Our dual AI analysis gives Viatris Inc a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VTRS's free cash flow?
Viatris Inc's operating cash flow is $388.3M, with capital expenditures of $39.9M. FCF margin is 9.9%.
How does VTRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 5.0% (avg: 12%), ROE 1.2% (avg: 15%), current ratio 1.60 (avg: 2).